NovoCure Limited (NASDAQ:NVCR) has received an average recommendation of “Buy” from the nine research firms that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $19.33.

Several equities research analysts have issued reports on NVCR shares. Aegis reaffirmed a “buy” rating and set a $14.00 price target on shares of NovoCure Limited in a report on Tuesday, April 18th. Zacks Investment Research raised NovoCure Limited from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a report on Wednesday, April 19th. Wedbush reaffirmed an “outperform” rating and set a $20.00 price target on shares of NovoCure Limited in a report on Thursday, April 27th. Deutsche Bank AG raised their price target on NovoCure Limited from $10.00 to $11.00 and gave the company a “hold” rating in a report on Friday, April 28th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating and set a $14.00 price target on shares of NovoCure Limited in a report on Monday, May 1st.

In other NovoCure Limited news, CEO Asaf Danziger sold 180,601 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $15.13, for a total transaction of $2,732,493.13. Following the transaction, the chief executive officer now owns 1,163,296 shares in the company, valued at approximately $17,600,668.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Pomona Capital Vii Fund Invest sold 1,072,532 shares of the stock in a transaction on Monday, June 26th. The stock was sold at an average price of $17.35, for a total value of $18,608,430.20. The disclosure for this sale can be found here. Insiders have sold a total of 2,265,522 shares of company stock worth $38,473,772 in the last quarter. Company insiders own 16.70% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Legal & General Group Plc boosted its position in NovoCure Limited by 8.5% in the second quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 1,092 shares during the last quarter. American International Group Inc. boosted its position in NovoCure Limited by 7.1% in the first quarter. American International Group Inc. now owns 31,191 shares of the medical equipment provider’s stock valued at $253,000 after buying an additional 2,065 shares during the last quarter. Bank of New York Mellon Corp boosted its position in NovoCure Limited by 1.4% in the first quarter. Bank of New York Mellon Corp now owns 173,523 shares of the medical equipment provider’s stock valued at $1,406,000 after buying an additional 2,480 shares during the last quarter. Teachers Advisors LLC boosted its position in NovoCure Limited by 3.3% in the first quarter. Teachers Advisors LLC now owns 98,799 shares of the medical equipment provider’s stock valued at $800,000 after buying an additional 3,125 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its position in NovoCure Limited by 11.7% in the second quarter. Nationwide Fund Advisors now owns 32,717 shares of the medical equipment provider’s stock valued at $566,000 after buying an additional 3,436 shares during the last quarter. Hedge funds and other institutional investors own 25.15% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/novocure-limited-nvcr-receives-average-rating-of-buy-from-brokerages/1490690.html.

NovoCure Limited (NVCR) opened at 19.05 on Tuesday. The company’s market cap is $1.70 billion. NovoCure Limited has a 12 month low of $5.95 and a 12 month high of $21.75. The company’s 50-day moving average is $18.69 and its 200-day moving average is $12.37.

NovoCure Limited (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.01. NovoCure Limited had a negative net margin of 75.91% and a negative return on equity of 69.48%. The business had revenue of $38.38 million for the quarter, compared to analyst estimates of $42.20 million. On average, equities research analysts anticipate that NovoCure Limited will post ($0.75) earnings per share for the current year.

NovoCure Limited Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Analyst Recommendations for NovoCure Limited (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.